ArticleMolecular & cellular oncology2026
Mutation detection in women diagnosed with endometrial cancer: a next-generation sequencing analysis.
Article in Molecular & cellular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is a heterogeneous gynecological malignancy characterized by diverse genetic and epigenetic alterations. This study investigated genetic mutations associated with EC among Kurdish women using next-generation sequencing (NGS). Seventy histopathologically confirmed EC cases were included, and peripheral blood DNA samples were analyzed. Whole-exome sequencing was performed on nine carefully selected cases based on specific clinical and pathological criteria, including early age of onset and/or family history suggestive of hereditary cancer predisposition, following enzymatic fragmentation, adapter ligation, PCR amplification, and targeted capture using biotinylated probes. The analysis identified five potentially significant variants in five genes: CHEK2, MUTYH, PLA2G2A, POLE, and USF3. The detected alterations included a heterozygous deletion in CHEK2 (p. Tyr113del), a homozygous SNP in MUTYH (p. Arg217His), heterozygous SNPs in PLA2G2A (p. Arg77Gly) and POLE (p. Ser2237Arg), and a heterozygous deletion in USF3 (p. Val576del). These findings highlight important molecular features of EC in Kurdish patients and may support future development of targeted therapeutic strategies. Further validation with larger cohorts is recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.